Blackhawk Plastic Surgery, Danville, California.
UltaMed Corporation, Fort Lauderdale, Florida.
Dermatol Surg. 2019 Dec;45(12):1580-1584. doi: 10.1097/DSS.0000000000001877.
Little literature exits on the mechanism of action of implanted polymethylmethacrylate (PMMA) filler.
To characterize PMMA-induced dermal extracellular matrix production in the skin.
Single-center, open-label prospective study in healthy volunteers undergoing removal of redundant skin was injected intradermally and subdermally with PMMA dermal filler (Bellafill). Punch biopsies were harvested over a time course and evaluated for the deposition of collagen-3 and procollagen-1, proteoglycans and elastin using immunohistochemistry. Blinded histopathologic readings were performed by a dermatopathologist to characterize the nature of the dermal extracellular matrix findings.
Normal inflammatory infiltrate was exhibited at all timepoints after PMMA injection with an influx of fibroblasts and new vasculature. Tissue proteoglycans were noted within the injectate beginning at Week 1 and persisted through the study end point. Increased collagen Type 3 was evident following the first week after injection, peaked at Month 2 and diminished through Months 3 through 6. Procollagen-1 was noted at Month 1 and continued to increase in intensity and organization through the study end point (6 months). Elastin staining was inconclusive. Polymethylmethacrylate microspheres remained within the initial injection area and became encapsulated within new collagen fibers. The growth and pattern of new connective tissue mimicked a normal wound healing response.
Polymethylmethacrylate-collagen gel filler stimulates collagen-3 and procollagen-1 when injected into human skin. This combination of neocollagenesis followed by microencapsulation of PMMA microspheres in the new tissue provides for long-lasting results.
关于植入聚甲基丙烯酸甲酯(PMMA)填充剂的作用机制,文献资料较少。
描述 PMMA 诱导皮肤细胞外基质产生的机制。
本研究为单中心、开放性、前瞻性研究,纳入在健康志愿者中进行多余皮肤切除手术的患者,将 PMMA 真皮填充剂(Bellafill)皮内和皮下注射入皮肤。在一段时间内采集活检标本,采用免疫组织化学法检测胶原蛋白-3 和前胶原蛋白-1、蛋白聚糖和弹性蛋白的沉积。由皮肤科病理学家进行盲法组织病理阅读,以描述真皮细胞外基质的性质。
PMMA 注射后所有时间点均表现出正常的炎症浸润,伴有成纤维细胞和新血管的涌入。在注射后第 1 周开始,在注射物中就可以观察到组织蛋白聚糖,并持续到研究终点。注射后第 1 周就可观察到胶原蛋白-3 增加,第 2 个月达到高峰,并在第 3 至 6 个月逐渐减少。第 1 个月可以观察到前胶原蛋白-1,并在研究终点(6 个月)时继续增加强度和组织化。弹性蛋白染色不明确。聚甲基丙烯酸甲酯微球仍保留在初始注射区域内,并被新的胶原纤维包裹。新结缔组织的生长和模式类似于正常的伤口愈合反应。
当 PMMA 胶原凝胶填充剂注入人体皮肤时,会刺激胶原蛋白-3 和前胶原蛋白-1 的产生。这种新胶原形成与 PMMA 微球在新组织中微囊化的结合,为持久的效果提供了保障。